Apoptosis and cell proliferation correlated with tumour grade in peritoneal fluids of patients with serous ovarian cancer

Cytopathology

Volumn 22, Issue 6, 2011, Pages 383-386

  Kalogeraki, A ^a   Karvela Kalogeraki, I ^a   Petraki, P E ^a   Zois, I ^a   Tamiolakis, D ^a   Stathopoulos, E N ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Apoptosis; Cytopathology; MIB 1; Ovarian carcinoma; Peritoneal fluid; Serous adenocarcinoma; TUNEL

Indexed keywords

KI 67 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; FEMALE; HUMAN; NICK END LABELING; OVARIAN SEROUS ADENOCARCINOMA; OVARY ADENOCARCINOMA; PERITONEAL FLUID; PRIORITY JOURNAL; PROGNOSIS;

AGED; APOPTOSIS; ASCITIC FLUID; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS;

EID: 81355149246     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2010.00797.x     Document Type: Article

References (15)

1. Tagi H, Miyamoto S, Tanaka Y et al. Clinical significance of heparin binding epidermal growth factor- like growth in peritoneal fluid of ovarian cancer. Br J Cancer 2005;92:1737-45.
2. Mills GB, May C, McGill M, Roifman CM, Mellers A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 1998;48:1066-71.
3. Preethi TR, Chacko P, Kesari L et al. Apoptosis in epithelial ovarian tumours. Pathol Res Pract 2002;198:273-80.
4. Ghazizadeh M, Sasaki Y, Araki T, Konishi H, Aihara K. Prognostic value of proliferative activity of ovarian carcinoma as revealed by PCNA and AgNOR analysis. Anat Pathol 1997;107:451-8.
5. Rowan S, Fisher DE. Mechanisms of apoptotic cell death. Leukemia 1997;11:457-65.
6. Javier de la Torre F, Garcia A, Gil Moreno A et al. Apoptosis in epithelial ovarian tumours: prognostic significance of clinical and histopathologic factors and its association with the immohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax). Eur J Obstet Gynecol Reprod Biol 2007;130:12-8.
7. Bast R, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-44.
8. Yap TA, Carten CT, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167-81.
9. Sengupta PS, McGown AT, Bajaj V et al. P53 and related proteins in epithelial ovarian cancer. Eur J Cancer 2000;36:2317-28.
10. Thomas H, Nasim MM, Sarraf CE. Proliferating cell nuclear antigen (PCNA) immunostaining- a prognostic factor in ovarian cancer. Br J Cancer 1995;71:357-62.
11. Viale G, Maisonneuve P, Banoldi E. The combine evaluation of p53 accumulation and Ki-67(MIB-1) labeling index provides independent information on overall survival of ovarian carcinoma patients. Ann Oncol 1997;8:469-76.
12. Garzetti GG, Giavattini A, Goteri G. Ki-67 antigen immunostaining (MIB-1 monoclonal antibody) in serous ovarian tumours: index of proliferating activity with prognostic significance. Gynaecol Oncol 1995;51:169-74.
13. Yamasaki F, Takunaga O, Sugimori H. Apoptotic index in ovarian carcinoma. Correlation with clinicopathologic factors and prognosis. Gynaecol Oncol 1997;66:439-48.
14. Kar R, Sen S, Signh A et al. Role of apoptotic regulators in human epithelial ovarian cancer. Cancer Biol 2007;6:1101-5.
15. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.